HUTCHMED (China) Limited (HK:0013) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HUTCHMED (China) Limited has announced a significant milestone, receiving a $10 million payment from Takeda following the first European reimbursement for FRUZAQLA® (fruquintinib) in Spain. This approval marks a crucial step in expanding access to this innovative colorectal cancer treatment across Europe. The drug, already approved in several countries, is part of a strategic partnership with Takeda to address unmet needs in cancer therapy.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.